Benefits (Research Focus) Combined GHRH + GHS-R activation studied for paired pathway stimulation of the somatotropic axis Pulsatile GH release investigated for physiologic-pattern growth hormone release in research models IGF-1 axis signaling explored for downstream hepatic IGF-1 production and somatotropic endpoints Receptor-pathway differentiation examined for paired GHRH receptor and GHS-R1a receptor pharmacology Hormone selectivity researched for ipamorelins reported minimal off-target effects on cortisol, prolactin, and ACTH What Researchers Look At Plasma GH and IGF-1 dynamics following paired peptide administration Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation Cortisol, prolactin, and ACTH response panels (selectivity markers) DPP-IV resistance and peptide pharmacokinetic profiles across components Comparative pharmacology versus tesamorelin-based blends and single-component administration Quick Specs Form: Lyophilized white powder CJC-1295 (no DAC): 5 mg per vial Ipamorelin: 5 mg per vial Total Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC (per component) Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound 1: CJC-1295 without DAC (Mod GRF 1-29) Synonyms: Mod GRF 1-29
According to the manufacturer, milder or more common Contrave side effects include: Abdominal pain Altered taste Anxiety Constipation Diarrhea Dizziness Dry mouth Excessive sweating Fatigue Headache Heart palpitations Hot flush Increase in blood pressure Increase in heart rate Influenza Insomnia Irritability Muscle strain Nausea Rash Ringing in ears Stomach virus Tremor Trouble sleeping Urinary tract infection Vomiting This is not a complete list of potential side effects
Yunfeng Liu, [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology ORCID: Yi Zhang, orcid.org/0000-0003-0305-3127 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Other measures, such as medically-guided diets or lifestyle changes in combination with other medications and therapies, should be explored first.
